Clinical Trials in Onychomycosis Research

Clinical trials in onychomycosis research are the mechanism through which every treatment improvement in nail fungus management ultimately reaches patients. Every antifungal drug currently prescribed — terbinafine, itraconazole, efinaconazole, ciclopirox, tavaborole — passed through structured clinical trials that demonstrated safety and efficacy before regulatory approval. Every treatment being described today as “emerging” will only become available if clinical trials in onychomycosis research produce the evidence required to support approval.

Understanding how these trials work, what they are currently investigating, and what results mean helps patients make sense of the treatment landscape — including the gap between what sounds promising in early research and what is actually available in a podiatrist’s office today. It also helps patients who may be interested in participating in trials to understand what that involvement looks like.

---

Why Onychomycosis Is an Active Research Target

Onychomycosis receives substantial ongoing research investment because of a clear unmet clinical need — existing treatments work well enough to treat most patients, but not well enough to satisfy several important criteria:

Cure rates are incomplete: Oral terbinafine — the most effective currently approved treatment — achieves mycological cure in 70 to 80 percent of patients. That means 20 to 30 percent of patients completing a full, appropriate treatment course do not achieve laboratory-confirmed clearance.

Recurrence is common: Even patients who clear their infection face 20 to 50 percent recurrence rates within 3 to 5 years — driven by persistent host susceptibility factors, environmental reexposure, and incomplete clearance of viable fungal organisms.

Treatment duration is long: The standard treatment course is 12 weeks of oral medication, followed by 12 to 18 months of nail growth to see the final result. This is a significant patient commitment.

Drug tolerability limits some patients: Significant drug interactions, liver monitoring requirements, and side effects like taste disturbance from terbinafine mean a meaningful proportion of patients cannot use the most effective available treatments.

Topical alternatives have modest efficacy: Prescription topical antifungals produce complete cure in only 5 to 18 percent of patients for established moderate toenail infection — a significant gap from oral treatment.

These clinical gaps define the research agenda for clinical trials in onychomycosis research.

---

How Clinical Trials Work: The Phase Structure

Clinical trials follow a structured regulatory process — the same whether the trial is for a new antifungal drug, a novel delivery system, or a device-based treatment like laser or PDT. Understanding this structure helps patients interpret what “in clinical trials” actually means for any given treatment.

Phase 1: Safety and Dosing

Phase 1 trials involve a small number of participants (typically 20 to 80) and focus on establishing that the treatment is safe in humans and identifying appropriate doses. These trials ask: does this cause harm, and at what doses?

Phase 1 trials for new antifungals may involve healthy volunteers or patients with the condition depending on the treatment’s risk profile.

For patients: A treatment in Phase 1 is genuinely early — significant uncertainty remains about both safety and efficacy. Phase 1 data is promising, not proven.

Phase 2: Efficacy and Expanded Safety

Phase 2 trials involve larger numbers of participants (typically 100 to 300) and begin evaluating whether the treatment actually works for the condition — while continuing to gather safety data. These trials ask: does this work, and is it still safe at this scale?

In onychomycosis Phase 2 trials, researchers typically assess outcomes like mycological cure rate (negative KOH and culture), clinical cure rate (nail appearance), and complete cure (both combined) at specified time points.

Phase 2 trial data for onychomycosis gives the most useful signal about whether a treatment is likely to succeed in Phase 3.

Phase 3: Comparative Effectiveness

Phase 3 trials are the pivotal trials required for regulatory approval — large (typically 300 to 3,000+ participants), randomized, often double-blind, and comparing the new treatment to the current standard of care or placebo.

For onychomycosis, Phase 3 trials typically:

• Randomize participants to new treatment vs comparator (placebo, vehicle, or active comparator)
• Follow participants for 12 to 18 months
• Assess complete cure and mycological cure as primary endpoints
• Collect safety data across the full participant population

For patients: Phase 3 data is the strongest evidence basis for treatment decisions. Regulatory agencies require Phase 3 trial data for drug approval.

Phase 4: Post-Marketing Surveillance

Phase 4 trials occur after regulatory approval and examine real-world effectiveness, long-term safety, effects in populations underrepresented in earlier trials (elderly, specific comorbidities), and comparative effectiveness against other approved treatments.

---

Current Areas of Active Clinical Trials in Onychomycosis Research

Novel Oral Antifungal Agents

Oteseconazole:
Oteseconazole is a novel azole antifungal with highly selective inhibition of fungal CYP51 — the enzyme required for ergosterol synthesis. Its selectivity for fungal rather than human CYP enzymes gives it a significantly better drug interaction profile than itraconazole (which inhibits human CYP3A4, creating dangerous statin and warfarin interactions).

Clinical trials in onychomycosis research with oteseconazole have progressed through Phase 2 and into Phase 3 for onychomycosis specifically. Published Phase 2 data shows promising mycological cure rates with a favorable safety profile. If Phase 3 results confirm these findings, oteseconazole would represent a meaningful advance for patients who cannot safely take itraconazole due to drug interactions.

Ibrexafungerp:
Ibrexafungerp represents a genuinely novel drug class — triterpenoid antifungals that inhibit fungal (1,3)-beta-D-glucan synthase (the same target as echinocandin IV antifungals, but orally bioavailable). This mechanism is entirely distinct from azoles and allylamines.

Phase 2 onychomycosis trials have been conducted. The novel mechanism is particularly interesting for potential resistance management — no cross-resistance with azoles or allylamines means this could be used in patients who have failed treatment with these classes.

Fosravuconazole (F2G)
Fosravuconazole is a prodrug azole with improved activity against dermatophytes compared to existing azoles. Phase 3 trials conducted in Japan led to approval there for dermatophyte nail infection; development for other markets continues.

Topical Delivery Innovation Trials

Several clinical trials in onychomycosis research are examining improved topical formulations that address the nail penetration barrier:

Iontophoresis-enhanced delivery:
Multiple research groups have conducted trials using small electrical currents to drive antifungal drug molecules through the nail plate (iontophoresis). Published Phase 2 studies have shown improved nail penetration compared to passive topical application of the same drugs. Phase 3 trials for this approach are in progress.

Ultrasound-mediated drug delivery:
Low-frequency ultrasound transiently increases the permeability of the nail plate, allowing antifungal drugs to penetrate more effectively. Clinical trials examining the combination of ultrasound with topical antifungal application have shown improved drug delivery in early-phase studies.

Nanoparticle antifungal formulations:
Several nanoparticle-based formulations of existing antifungal compounds (primarily azoles and allylamines) are in early to mid-stage clinical trials. These formulations demonstrate substantially improved nail penetration in ex vivo and animal studies; human trial data is accumulating but large Phase 3 datasets are not yet published.

Photodynamic Therapy (PDT) Trials

Photodynamic therapy for onychomycosis is one of the most actively studied areas in clinical trials in onychomycosis research. Multiple Phase 2 and Phase 3 trials have been conducted examining different photosensitizers and light delivery protocols.

Key published findings from PDT trials:

• Complete cure rates ranging from 30 to 72 percent depending on protocol, photosensitizer, infection severity, and number of sessions
• Consistent evidence that PDT combined with nail debridement produces better outcomes than PDT alone
• Combination PDT + topical antifungal showing improved outcomes compared to PDT alone
• Favorable safety profile across multiple trials

The current evidence status of PDT: PDT for onychomycosis has more clinical trial data than most other emerging approaches, but clinical guidelines have not yet incorporated it as a standard recommendation due to lack of standardized protocols and variable results across trials. It is in active clinical use in some specialist practices while its evidence base continues to develop.

Laser Device Trials

Clinical trials in onychomycosis research examining laser therapy have been numerous but methodologically variable. The challenge in interpreting laser trial data:

• Many trials use “clinical improvement” or “increased clear nail” as endpoints rather than mycological cure (the stronger endpoint requiring negative culture)
• Comparator conditions vary — some trials compare to sham treatment, others to no treatment, few to active antifungal medication
• Follow-up periods are often shorter than in drug trials
• Industry funding of many trials raises independent replication concerns

The current evidence summary from laser trials: Clinical improvement in nail appearance is consistently demonstrated. Mycological cure (confirmed laboratory eradication) rates are more variable and generally lower than oral terbinafine when directly compared. The FDA clearance language (“temporary increase in clear nail”) accurately reflects the evidence level.

Ongoing trials examining specific improvements to laser protocols — optimized wavelengths, combination with topical medication immediately post-treatment, fractional channeling approaches — may produce stronger evidence in coming years.

Vaccine and Immunotherapy Research

The most early-stage area of clinical trials in onychomycosis research involves vaccine and immunotherapy approaches:

Dermatophyte antigen vaccines: Several research groups have identified candidate antigens — proteins from dermatophyte organisms that could stimulate protective immune responses. Animal studies have demonstrated immune protection. Human Phase 1 trials have begun in some programs.

Immune checkpoint modification: Research examining whether modifying the immune response to dermatophytes — potentially through checkpoint inhibitor approaches — could enhance clearance of established infection. This is highly early-stage.

Realistic timeline assessment: Antifungal vaccines for nail fungus are in early Phase 1 development at best. Clinical availability for patients is many years away and depends on successful Phase 1, 2, and 3 progression — a process that typically takes 10 or more years even for trials proceeding without major setbacks.

---

What Endpoints Mean in Onychomycosis Trials

Understanding what outcomes clinical trials in onychomycosis research are measuring helps patients interpret trial results meaningfully:

Mycological cure: Negative KOH microscopy AND negative fungal culture — confirmed laboratory elimination of fungal organisms. The most clinically meaningful endpoint for antifungal efficacy.

Clinical cure (clinical success): The nail appears clear or nearly clear by clinical assessment — a defined nail appearance score. Can be achieved without confirmed laboratory clearance.

Complete cure: Both mycological cure AND clinical cure simultaneously. The most demanding endpoint and most clinically meaningful for the patient experience.

Treatment failure: Persistence of positive laboratory findings and/or clinical evidence of infection at the defined endpoint.

Recurrence rate: How many patients who achieved cure at the primary endpoint have reinfection at later time points (6 months, 12 months, 36 months post-treatment).

The gap between these endpoints explains why some treatments show impressive-sounding results in marketing materials while the published trial data for mycological cure is much less dramatic.

---

How Patients Can Participate in Clinical Trials

Patients with onychomycosis who are interested in participating in clinical trials in onychomycosis research have several options:

ClinicalTrials.gov: The US National Library of Medicine’s registry lists essentially all clinical trials involving human participants. Searching “onychomycosis” on this platform shows current recruiting trials — including information on eligibility criteria, locations, and contact information.

WHO International Clinical Trials Registry Platform (ICTRP): For trials registered outside the US, this WHO registry aggregates registries from multiple countries.

Academic medical centers: Teaching hospitals and academic medical centers are the most common sites for clinical trials in onychomycosis research. Patients in proximity to major academic dermatology or podiatry programs may be able to enroll in trials through those institutions.

Pharmaceutical sponsor programs: Companies conducting Phase 2 and Phase 3 trials actively recruit participants through their clinical sites and sometimes through patient advocacy networks.

What participation typically involves:

• Eligibility screening (confirming the diagnosis, infection characteristics, health status)
• Laboratory confirmation of active fungal infection
• Randomization to treatment or comparator (in blinded trials, participants do not know which they receive)
• Regular visits for efficacy and safety assessment over the study period
• Compensation may be provided for participation time and travel in some trials

---

The Connection Between Clinical Trials and Treatment Decision Today

Understanding clinical trials in onychomycosis research helps patients contextualize current treatment:

Treatments available today — oral terbinafine, itraconazole, prescription topical antifungals — are backed by the strongest existing evidence. The Phase 3 trial data supporting these treatments is substantial, which is why they remain guideline-recommended standard of care.

Treatments being studied — novel oral agents, PDT, nanoparticle formulations, enhanced laser protocols — have promising early data but are not yet available to the general patient population through standard care. They may be accessible through trial participation.

Treatments on the distant horizon — antifungal vaccines, immunotherapy — are genuinely promising directions that are not clinically relevant for current treatment decisions but represent meaningful progress in the field’s longer-term trajectory.

---

Frequently Asked Questions About Clinical Trials in Onychomycosis Research

Are clinical trials for nail fungus safe?

Clinical trials follow strict ethical and safety protocols under regulatory oversight. All participants provide informed consent explaining the trial’s purpose, procedures, risks, and their right to withdraw at any time. Phase 1 trials involve more uncertainty about safety; Phase 3 trials for onychomycosis typically involve drugs or approaches with established Phase 1 and 2 safety data.

Do clinical trial participants receive free treatment?

In many trials, the investigational treatment is provided at no cost to participants. Some trials also compensate for time and travel. However, standard medical care costs are typically the participant’s responsibility. Trial-specific financial arrangements are outlined in the informed consent document.

How do clinical trials in onychomycosis research compare nail treatments?

Pivotal Phase 3 trials typically compare the new treatment to either placebo/vehicle or to the current standard of care. For onychomycosis, the standard of care comparator is often oral terbinafine or a vehicle control (inactive topical base). The choice of comparator directly affects how meaningful the trial results are.

Where can I find current nail fungus clinical trials?

Search clinicaltrials.gov for “onychomycosis” to find currently recruiting trials. The site shows eligibility criteria, locations, contact information, and the phase of each trial. Academic medical centers and dermatology teaching hospitals are the most common enrollment sites.

---

Summary

Clinical trials in onychomycosis research are actively producing the next generation of nail fungus treatments — addressing the real gaps in current care around cure rates, drug tolerability, treatment duration, and recurrence. The most advanced pipeline includes novel oral antifungals with better drug interaction profiles (oteseconazole, ibrexafungerp, fosravuconazole), enhanced topical delivery systems (iontophoresis, ultrasound, nanoparticle formulations), and photodynamic therapy with a growing evidence base already reaching specialist clinical practice.

Understanding how these trials work — the phase structure, the endpoints used, and what “clinical improvement” versus “mycological cure” actually means — helps patients critically evaluate treatment claims and make informed decisions.